DoW Lupus, Transformative Vision Development Award
Closed Posted
- Opportunity number
- HT942526LRPTVDA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Defense Health Agency, through the Department of the Army Medical Command, is seeking planning, development activities, and pilot studies that generate preliminary data and demonstrate feasibility for future lupus interventional research. Applicants must address at least one of two focus areas: improving lupus outcomes through innovative healthcare delivery models or designing interventions to improve quality of life and mental health at individual or healthcare system levels. Key requirements include the mandatory inclusion of at least one lupus consumer advocate as an integral research team member, with Principal Investigators limited to independent (non-mentored) positions and restricted to one application per funding mechanism. The evaluation process employs a two-tier review system assessing technical merit (including research strategy, feasibility, impact, and personnel qualifications), followed by programmatic review evaluating peer ratings, relevance to Lupus Research Program priorities, and portfolio composition. Critical deadlines include the pre-application submission (Letter of Intent) due July 29, 2026 at 5:00 p.m. ET and full application submission due August 19, 2026 at 11:59 p.m. ET, with peer review scheduled for October 2026 and programmatic review for February 2027.
Approximately $500,000 in total funding is available to support approximately two applications, with a maximum award of $250,000 per application and a maximum 2-year performance period. The mechanism supports phase 0/1 clinical trials but explicitly prohibits phase 2/3 clinical trials and animal studies. Research will be conducted at eligible extramural and intramural U.S. Department of War organizations, including foreign and domestic entities and for-profit and nonprofit organizations, with awards expected by September 30, 2027, utilizing FY26 funds expiring September 30, 2032.
Synopsis
Summary: This funding mechanism supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study. Successful studies may be submitted to a future Lupus Research Program (LRP) Transformative Vision Award (TVA), or equivalent, for funding consideration (See Funding Opportunity Number HT942526LRPTVA for additional information). Research must address at least one of the fiscal year 2026 (FY26) LRP Transformative Vision Development Award (TVDA) focus areas. This funding mechanism allows for phase 0/1 clinical trials, if appropriate. The mechanism does not allow for phase 2/3 clinical trials or animal studies.
Distinctive Features:
• Preliminary data are permitted but not required.
• Applications must include at least one lupus consumer advocate as a member of the research team.
• An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, Impact Award, TVDA, TVA), for a maximum of four applications to the FY26 LRP.
Files
| File | Type | Posted |
|---|---|---|
| HT942526LRPTVDA_GG.pdf | ||
| HT942526LRPTVDA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity